1.Artificial Intelligence in Surgery and Its Potential for Gastric Cancer
Takahiro KINOSHITA ; Masaru KOMATSU
Journal of Gastric Cancer 2023;23(3):400-409
Artificial intelligence (AI) has made significant progress in recent years, and many medical fields are attempting to introduce AI technology into clinical practice. Currently, much research is being conducted to evaluate that AI can be incorporated into surgical procedures to make them safer and more efficient, subsequently to obtain better outcomes for patients.In this paper, we review basic AI research regarding surgery and discuss the potential for implementing AI technology in gastric cancer surgery. At present, research and development is focused on AI technologies that assist the surgeon's understandings and judgment during surgery, such as anatomical navigation. AI systems are also being developed to recognize in which the surgical phase is ongoing. Such a surgical phase recognition systems is considered for effective storage of surgical videos and education, in the future, for use in systems to objectively evaluate the skill of surgeons. At this time, it is not considered practical to let AI make intraoperative decisions or move forceps automatically from an ethical standpoint, too. At present, AI research on surgery has various limitations, and it is desirable to develop practical systems that will truly benefit clinical practice in the future.
2.Five-year Survival Associated with Stage I Gastric Cancer after Resection of Early Recurrence at Nodal Station No. 14v: a Case Report.
Iku ABE ; Takahiro KINOSHITA ; Akio KAITO ; Hideki SUNAGAWA ; Masahiro WATANABE ; Shizuki SUGITA ; Akiko TONOUCHI ; Reo SATO
Journal of Gastric Cancer 2017;17(2):186-191
The role of nodal station No. 14v (along the superior mesenteric vein) in lymphadenectomy for distal gastric cancer remains elusive. A 73-year-old woman underwent endoscopic submucosal dissection for gastric cancer, and was referred to our division for additional surgery because of pathologically non-curative resection. A laparoscopic distal gastrectomy with D1+ dissection was performed, with a final diagnosis of pT1bN1M0, Stage IB (2 nodal metastases to No. 6). Four months post-surgery, abdominal computed tomography revealed a 14-mm solitary nodule along the superior mesenteric vein. The lesion was excised and pathologically identified as a lymph node metastasis. Adjuvant chemotherapy with tegafur-gimeracil-oteracil potassium (S-1) was administered for the metastasis. Presently the patient survives without recurrence, 5.5 years after the second operation. Our findings suggest that there is lymphatic flow from the No. 6 to the No. 14v nodal station. Some patients with a No. 6 metastasis may benefit from a No. 14v lymphadenectomy, even in early-staged disease.
Aged
;
Chemotherapy, Adjuvant
;
Diagnosis
;
Early Detection of Cancer
;
Female
;
Gastrectomy
;
Humans
;
Lymph Node Excision
;
Lymph Nodes
;
Mesenteric Veins
;
Neoplasm Metastasis
;
Potassium
;
Recurrence*
;
Stomach Neoplasms*
3.Non-Randomized Confirmatory Trial of Laparoscopy-Assisted Total Gastrectomy and Proximal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG1401.
Kozo KATAOKA ; Hitoshi KATAI ; Junki MIZUSAWA ; Hiroshi KATAYAMA ; Kenichi NAKAMURA ; Shinji MORITA ; Takaki YOSHIKAWA ; Seiji ITO ; Takahiro KINOSHITA ; Takeo FUKAGAWA ; Mitsuru SASAKO
Journal of Gastric Cancer 2016;16(2):93-97
Several prospective studies on laparoscopy-assisted distal gastrectomy for early gastric cancer have been initiated, but no prospective study evaluating laparoscopy-assisted total gastrectomy or laparoscopy-assisted proximal gastrectomy has been completed to date. A non-randomized confirmatory trial was commenced in April 2015 to evaluate the safety of laparoscopy-assisted total gastrectomy and laparoscopy-assisted proximal gastrectomy for clinical stage I gastric cancer. A total of 245 patients will be accrued from 42 Japanese institutions over 3 years. The primary endpoint is the proportion of patients with anastomotic leakage. The secondary endpoints are overall survival, relapse-free survival, proportion of patients with completed laparoscopy-assisted total gastrectomy or laparoscopy-assisted proximal gastrectomy, proportion of patients with conversion to open surgery, adverse events, and short-term clinical outcomes. The UMIN Clinical Trials Registry number is UMIN000017155.
Anastomotic Leak
;
Asian Continental Ancestry Group
;
Conversion to Open Surgery
;
Gastrectomy*
;
Humans
;
Japan*
;
Laparoscopy
;
Medical Oncology*
;
Non-Randomized Controlled Trials as Topic
;
Prospective Studies
;
Stomach Neoplasms*